Gennex Laboratories Ltd
Incorporated in 1995, Gennex Laboratories Ltd manufactures Bulk Drugs and Intermediaries[1]
- Market Cap ₹ 318 Cr.
- Current Price ₹ 13.1
- High / Low ₹ 19.0 / 10.8
- Stock P/E 22.0
- Book Value ₹ 8.67
- Dividend Yield 0.00 %
- ROCE 10.5 %
- ROE 7.98 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 51.4% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 23.6%
- Company has a low return on equity of 8.38% over last 3 years.
- Earnings include an other income of Rs.7.02 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35 | 32 | 39 | 42 | 44 | 56 | 56 | 60 | 61 | 65 | 67 | 95 | 106 | |
| 33 | 30 | 34 | 37 | 42 | 52 | 52 | 53 | 56 | 61 | 54 | 84 | 92 | |
| Operating Profit | 2 | 2 | 4 | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 12 | 10 | 13 |
| OPM % | 5% | 6% | 11% | 11% | 5% | 7% | 6% | 11% | 9% | 7% | 19% | 11% | 12% |
| 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 3 | 4 | 9 | 7 | |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 15 | 17 | 17 |
| Tax % | 70% | 23% | 23% | 13% | 42% | 26% | 27% | 20% | 23% | 24% | 20% | 18% | |
| 0 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 12 | 14 | 14 | |
| EPS in Rs | 0.01 | 0.03 | 0.12 | 0.14 | 0.04 | 0.12 | 0.10 | 0.21 | 0.21 | 0.26 | 0.52 | 0.62 | 0.63 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 11% |
| 3 Years: | 16% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 51% |
| 3 Years: | 54% |
| TTM: | -3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 24% |
| 3 Years: | 29% |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 9% |
| 3 Years: | 8% |
| Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 18 | 23 | 23 | 24 |
| Reserves | 13 | 13 | 16 | 18 | 19 | 21 | 23 | 27 | 31 | 61 | 148 | 162 | 186 |
| 3 | 4 | 2 | 4 | 2 | 5 | 5 | 7 | 10 | 1 | 1 | 1 | 22 | |
| 11 | 10 | 11 | 14 | 16 | 13 | 16 | 12 | 14 | 16 | 34 | 32 | 33 | |
| Total Liabilities | 40 | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 96 | 205 | 218 | 266 |
| 16 | 15 | 15 | 16 | 16 | 16 | 15 | 14 | 14 | 15 | 16 | 20 | 20 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 |
| Investments | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 |
| 16 | 18 | 19 | 26 | 28 | 29 | 35 | 38 | 48 | 73 | 180 | 188 | 234 | |
| Total Assets | 40 | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 96 | 205 | 218 | 266 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 3 | -0 | 3 | 2 | -2 | -1 | 7 | -14 | -33 | -10 | |
| -1 | -0 | -1 | -1 | -1 | -1 | -0 | -0 | -1 | -1 | 1 | 3 | |
| 0 | 0 | -2 | 1 | -2 | 1 | -0 | 2 | 2 | 21 | 79 | 2 | |
| Net Cash Flow | 0 | 0 | 0 | -0 | 0 | 2 | -2 | 0 | 7 | 6 | 47 | -5 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 71 | 66 | 90 | 87 | 68 | 41 | 55 | 67 | 49 | 74 | 46 |
| Inventory Days | 29 | 23 | 47 | 43 | 31 | 57 | 78 | 50 | 72 | 133 | 148 | 133 |
| Days Payable | 117 | 121 | 114 | 139 | 161 | 88 | 86 | 59 | 72 | 58 | 133 | 58 |
| Cash Conversion Cycle | -38 | -27 | -0 | -7 | -43 | 38 | 34 | 46 | 67 | 125 | 90 | 120 |
| Working Capital Days | 37 | 48 | 54 | 74 | 75 | 56 | 87 | 107 | 87 | 234 | 466 | 395 |
| ROCE % | 4% | 5% | 12% | 12% | 6% | 10% | 8% | 14% | 12% | 11% | 13% | 11% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Nov - Newspaper Publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30, 2025 announced by the Board in its …
- Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2025 14 Nov
-
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2025
14 Nov - Unaudited Q2/H1 results (Sep 30, 2025): standalone net profit Rs453.32L; consolidated Rs551.15L.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Nov - Newspaper Publication regarding Meeting of the Board of the Company scheduled to be held on Friday, November 14, 2025 for adoption of Unaudited (Standalone and …
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2025
4 Nov - Board meeting Nov 14, 2025 at 4:00 PM to approve Q2/H1 Sep 30, 2025 unaudited results; trading window timing.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
GLL is an ISO 9001:2008, TUV, ISO 14001 and OSHAS 18000 certified vertically integrated Active Pharmaceutical Ingredient manufacturer & exporter of Bulk Drugs, Intermediates and Biotech Products in the form of Expectorants,
Muscle Relaxants, Analgesic and Anti Fungal, etc.